KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.

Aleksandar Videnovic, Christopher S Coffey, Elizabeth B Klerman, Merit Cudkowicz, Hyun Joo Cho, Amy Amara, Karen Marder, Phyllis Zee, Christina Desir, Holly Ernst, Erin Steinhart, Michelle Costigan, Anna Gudjonsdottir, Elizabeth Klingner, Dixie Ecklund, Marianne Chase, Amy Wang, David Charles, David Clifford, Juliana Coleman, Alberto J Espay, Albert Y Hung, Srinath Kadimi, Annie Killoran, Lan Luo, Roneil Malkani, Jason Margolesky, Jennifer Marsella, Carine Maurer, Dragos Mihaila, Paolo Moretti, Ariane Park, Nicolas Phielipp, Harini Sarva, Binit Shah, Holly A Shill, Andrew Siderowf, Valerie Suski, Jessica Tate, Winona Tse, Kara Wyant, Lin Zhang, Christine Annis, Katherine Ambrogi, Gabrielle Auerbach, Melanie Benge, Emma Blystone, Loraine Brenner, Carolina Burgos Aguilar, Grace Bwala, Juliana Dorsch, Erica Goude, Hilda Gutierrez, Kelly Harper, Samuel Hochberger, Priyanka Kalyani, Jessica Lamb, Kay Maupin, Angela Molloy, Sherri Mosovsky, Mysha Sissine, Julie Steele, Monica Szela, Mangesha Teshome, Marie Wencel, Eric A Macklin, NeuroNEXT NN110 ENLITE PD Investigators

Mov Disord 40(11) 2445-2456

PMID40913446
PMCIDPMC13287846
DOI10.1002/mds.70009
发表日期2025-09-06
摘要

摘要

BACKGROUND: Light therapy (LT) in Parkinson's disease improves sleep. Specific LT parameters require further study, including optimal frequency. OBJECTIVES: We aimed to determine if once- or twice-daily bright white light therapy (BWLT) improves sleep. Secondary aims compared once-weekly BWLT to twice-daily dim red light therapy (DRLT) as controls, estimated effects on fatigue, and adherence. METHODS: A 16-week, randomized, phase 2, sham-controlled, dose-selection trial to select the superior BWLT frequency based on change in Parkinson's Disease Sleep Scale-2 (PDSS-2), participant burden, and safety. Participants were randomized to 8 weeks of twice-daily BWLT, once-daily BWLT, once-weekly BWLT, or twice-daily DRLT. An improvement of ≥1.7 points in 8-week change of PDSS-2 by daily BWLT relative to either control warranted advancing to a phase 3 trial. RESULTS: A total of 150 participants were randomized (mean [SD], 67 [8.6] years; 57 [38%] female; PDSS-2 17.1 [6.7]). Mean 8-week change from baseline in PDSS-2 score improved (twice-daily BWLT -2.6 [95% CI: -4.4, -0.7]; once-daily BWLT -1.5 [-3.3, 0.3]; once-weekly BWLT -0.4 [-2.2, 1.4]; twice-daily DRLT -1.8 [-3.6, 0.1]) but did not meet criteria for advancing. Mean 8-week change from baseline in Parkinson's Disease Fatigue Scale (PFS-16) score improved (twice-daily BWLT -6.4 [-9.8, -3.0]; once-daily BWLT -2.2 [-5.5, 1.1]; once-weekly BWLT -0.5 [-3.9, 2.8]; and twice-daily DRLT -3.8 [-7.3, -0.4]). Mean adherence to LT was 63%-86%. CONCLUSIONS: ENLITE-PD did not meet the criteria for advancing daily LT to a phase 3 trial. LT was safe and well-tolerated with good adherence. Once-weekly BWLT was a non-inferior control compared with twice-daily DRLT. © 2025 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。